In July 2005 Corixa Corporation was acquired by GlaxoSmithKline plc. with the firm formally closing down in 2006. Previously called Iasys Corporation (changed in FY 95), Corixa Corporation had been a research-based biotechnology company, primarily engaged in the research, development, and commercialization of products useful in preventing, treating or diagnosing cancer, certain infectious diseases and certain autoimmune diseases. With a lab and production facility also in Montana, Corixa Corporation developed immunotherapeutic products that address various infectious and inflammatory diseases, allergies, and cancers. The company initially focused on developing cancer therapies, but its success with vaccine adjuvants (additives that boost the immune system) has led the firm to change course.The company provided Adjuvants, which boosts the bodys immune response; and TLR4 Agonists and Antagonists, which interacts with bodys immune system and initiates the bodys innate immune response. Its Adjuvants in vaccines protect against diseases, including hepatitis B, cervical cancer, genital herpes, malaria, tuberculosis, lung cancer, allergy, and breast cancer. The companys Agonists include immune agents for seasonal allergic rhinitis, stimulating resistance to viral and bacterial pathogens, and for perennial rhinitis. Its Antagonists are used as an anti-inflammatory compound in IBD and other inflammatory disease indications.